

HOSTS



Professor Jerome Sarris
Deputy Director, NICM Health
Research Institute, Western
Sydney University

Professor Jerome Sarris has a particular interest in anxiety and mood-disorder research pertaining to nutraceutical psychopharmacology in complementary and integrative medicine, lifestyle medicine and psychotropic plant medicine research. Moving from clinical practise as a naturopath, nutritionist and acupuncturist to academia, Professor Sarris completed his doctorate at The University of Queensland in the field of psychiatry. He undertook his postdoctoral training at The University of Melbourne, Swinburne University of Technology and Harvard Medical School, and has been published in eminent journals including The American Journal of Psychiatry and The Lancet Psychiatry.



Justin Sinclair
Research Fellow, NICM Health
Research Institute, Western
Sydney University

Mr Justin Sinclair's key focus areas surrounding medicinal cannabis span several scientific disciplines, including cultivation, botany, genetics, ethnopharmacology, therapeutic applications and phytochemistry. He coordinates the Australian Medicinal Cannabis Research and Education Collaboration at NICM Health Research Institute and heads the Scientific Advisory Board for United In Compassion, Australia's leading medicinal cannabis advocacy group, which was instrumental in lobbying for government legislation related to medicinal cannabis. Mr Sinclair is also an Associate Member of both the Society of Cannabis Clinicians and the International Cannabinoid Research Society.

SPEAKERS




Dr Suzanne Sisley, MD
Principal Investigator
and President,
Scottsdale Research
Institute

Dr Suzanne Sisley is an Arizona-based physician practising internal medicine and psychiatry, and serves as Principal Investigator for the only FDA-approved trial examining the efficacy of whole-plant marijuana in combat veterans with treatment-resistant post-traumatic stress disorder. She is also a member of Nevada ILAC Medicinal Cannabis Commission, where she outlines regulations for laboratory testing, including limits on pesticides, residual solvents and other guidelines that are currently being used as a model for other states' medicinal cannabis laws.



**Adjunct Professor
John Skerritt**
Deputy Secretary,
Health Products
Regulation Group,
Therapeutic Goods
Administration,
Department of Health

Adjunct Professor John Skerritt has specific responsibility for the Therapeutic Goods Administration and the Office of Drug Control. He has extensive experience in medical, agricultural and environmental policy, as well as regulation, research management, technology application and commercialisation. He is an Adjunct Professor at the Universities of Sydney, Queensland and Canberra, and is a graduate of the Senior Executive Programs of London Business School and of the International Institute for Management Development in Switzerland.



Dr Mark J. Rosenfeld
Chief Executive Officer
and Chief Science
Officer, ANANDA
Scientific

Dr Mark J. Rosenfeld is the founder of a global company centered on making cannabinoids real, evidence-based human medicine. A molecular biologist with substantial pharmacological experience, his main laboratory is in Israel, where cannabinoids have been uniquely rendered into highly bioavailable formulations – the key to making consequential therapeutics. Prior achievements include developing tests to detect cancer and resolving how to readily breed giant pandas. He was the American scientist on the United Nations Bird Flu Committee as well as Medical Advisor to both the US Congress and China Ministry of Health.



**Associate Professor
Tim Karl** Associate
Professor of
Behavioural
Neuroscience, School
of Medicine, Western
Sydney University

Associate Professor Tim Karl is a behavioural neuroscientist focusing on preclinical research into the aetiology and therapy of brain disorders, including schizophrenia, dementia and amyotrophic lateral sclerosis. His team considers both detrimental and therapeutic effects of cannabis constituents, in particular cannabidiol (CBD), in established mouse models for these disorders. He is currently Lead Investigator of two NHMRC-funded project grants evaluating the potentially beneficial properties of CBD treatment for schizophrenia and dementia.

SPEAKERS



Associate Professor Jonathon Arnold
Lambert Initiative for Cannabinoid Therapeutics, and Associate Professor of Pharmacology, Faculty of Medicine and Health, The University of Sydney

Associate Professor Jonathon Arnold is the Associate Director of Preclinical Research at The University of Sydney's Lambert Initiative for Cannabinoid Therapeutics. With a focus on strategic direction, he works closely with the clinical research team to assist in the development and translation of research findings. This year, he was Advisor to the World Health Organisation's 40th Expert Committee on Drug Dependence Pre-Review on cannabis and cannabis-related substances.



Dr Katrina Green
Lecturer, School of Medicine, Faculty of Science, Medicine and Health, The University of Wollongong

Dr Katrina Green's research examines novel approaches to improving the pharmacological treatment of psychiatric illness and cognitive impairment. She has expertise in clinically relevant drug dosing, disease modelling, behavioural testing and neurochemical analyses in rodents. Dr Green's team has been examining the ability of cannabidiol (CBD) to improve cognition in a rodent model of schizophrenia, and the effects of CBD on chemical signalling systems in the brain. She is also a member of the Australian Centre for Cannabinoid Clinical and Research Excellence.



Professor Iain McGregor
Lambert Initiative for Cannabinoid Therapeutics, and Professor of Psychopharmacology, School of Psychology, Faculty of Science, The University of Sydney

Professor Iain McGregor is the Academic Director of The University of Sydney's Lambert Initiative for Cannabinoid Therapeutics and an NHMRC Principal Research Fellow. He is responsible for academic and organisational leadership, strategic direction, governance, and the development and achievement of the preclinical and clinical research strategies. Renowned in the field of medicinal cannabis research, he leads strategic relations, advocacy and education.



Associate Professor Judith Lacey
Head of Supportive Care, Chris O'Brien Lifehouse, Adjunct Associate Professor, NICM Health Research Institute, Western Sydney University, and Clinical Senior Lecturer, School of Medicine, Faculty of Medicine and Health, The University of Sydney

Dr Judith Lacey has been working as a physician for more than two decades. Over the past 15 years, she has worked extensively with cancer patients and people living with incurable illnesses. With a focus on holistic care, she is experienced in working together with complementary therapists, psychologists and other medical specialists and allied health professionals to maximise patient wellbeing.

SPEAKERS



Professor Nadia Solowij
Professor, School of Psychology and Illawarra Health and Medical Research Institute, University of Wollongong, and Co-Director, ACRE

Professor Nadia Solowij is Co-Director of the NHMRC-funded Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE). She has been researching the effects of long-term cannabis use for more than 25 years, and is now the most published researcher in the world on the topic of cannabis and the brain. Her recent research focused on the effects of different cannabinoids on brain structure, function, symptoms and cognition in naturalistic exposure studies and in experimental clinical trials with THC and CBD in humans.



Associate Professor Peter Grimison
Medical Oncologist, Chris O'Brien Lifehouse, and Clinical Associate Professor, School of Medicine, Faculty of Medicine and Health, The University of Sydney

Medical Oncologist and Clinical Associate Professor Peter Grimison leads national and international clinical trials of new treatments that could reduce deaths of young men suffering aggressive forms of testicular cancer, and is Study Chair for a clinical trial (funded by NSW Health) evaluating the efficacy of medicinal cannabis for chemotherapy-induced nausea and vomiting. His clinical work focuses on testicular cancer, other genito-urinary cancers, and upper gastrointestinal cancers.



Professor Nick Lintzeris
Conjoint Professor, Discipline of Addiction Medicine, Central Clinical School, and Director and Senior Staff Specialist, South Eastern Sydney Local Health District, NSW Health

Professor Nick Lintzeris has worked in the alcohol and other drugs sector for more than 25 years, in clinical, research and policy roles. His primary research interest is the development and evaluation of treatment interventions and services for individuals with substance-use disorders, with particular expertise in the evaluation of pharmacotherapies in treatment populations. He conducts treatment intervention studies, systematic reviews, service evaluation, psychopharmacology and epidemiology.



Professor Con Stough
Professor of Cognitive Neuroscience and Psychology, and Co-Director, Centre for Human Psychopharmacology, Swinburne University of Technology

Professor Con Stough's research aims for a better understanding of the cognitive and psychological effects of pharmacologically active substances, ranging from illicit drugs to herbal and nutrient medicines. This includes validating new and existing nutritional products that may have a pharmacological profile useful in cognitive enhancement – for example, the bacopa extract CDRI08. More broadly, his research contributes to the development of nutritional products in Australia and overseas that can improve brain and cognitive function.

SPEAKERS



Emeritus Professor Laurie Mather
Sydney Medical School,
The University of
Sydney

Emeritus Professor Laurie Mather's publications include Australia's first analysis of the chemical composition of cannabis (with pharmacognosist Lorna Cartwright, in 1972), as well as others on various aspects of cannabis and cannabinoids used medicinally. He has also been an author of formal submissions on medicinal uses of cannabis for various parliamentary inquiries, as well as articles for the press. In 2000, he was a member of the working party convened by Premier Bob Carr, to examine the case for introducing legislation to permit the medicinal use of cannabis in NSW.




Dr Maggie Davidson
Lecturer, Environmental
Health and
Management, Natural
Science, School of
Science and Health,
Western Sydney
University

Dr Maggie Davidson is a practising occupational hygienist working as a Lecturer and Researcher at Western Sydney University. She is also a Researcher with Australian Medicinal Cannabis Research and Education Collaboration, and Adjunct Researcher at Edith Cowan University. Her current research projects include farm to pharmacy, promoting workplace health and safety in the emerging Australian cannabis industry, biological hazards associated with thermal-comfort water-misting systems, and the pro-inflammatory potential of plant dusts.



Professor Jan Copeland
Director NCPIC, Faculty
of Medicine, The
University of New South
Wales (UNSW), and
Associate Investigator,
ACRE

Professor Jan Copeland was the founding and sole Director of the National Cannabis Prevention and Information Centre (NCPIC) at UNSW Australia and is now leading her own consultancy Cannabis Information and Support. She is an Associate Investigator with the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE) in the quality and safety in the implementation of medicinal cannabis use in the community. Professor Copeland has worked in the addictions field at UNSW for almost 30 years.



Dr Jeff Hergenrath
Medicinal Cannabis
Consultant and
Founding Member
of Society of
Cannabis Clinicians

Dr Jeff Hergenrath has been a founding member of the Society of Cannabis Clinicians since 2000, and President since 2008. His medical experience includes 26 years in emergency medicine and private general practice that has included the medicinal use of cannabis since 1977. He continues in an active consultation practice in California, providing cannabis recommendations to people with serious medical conditions. He is a member of the International Cannabinoid Research Society and the International Association for Cannabinoids in Medicine.